Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes

Study Identifier:
P06-001
ClinicalTrials.gov Identifier:
NCT01192425
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Hemoglobinuria
Study Drug
    Date
    N/A - N/A
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 10+ years
    Requirements Information
    Inclusion and Exclusion Criteria
    Inclusion Criteria
    • At least 10 years of age.
    • Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes
    Exclusion Criteria
    • Has any condition that might interfere with the patient's participation
    Sex
    Female & Male
    Age
    10+ years

    Study Details

    Medical Condition
    • Hemoglobinuria
    Study Drug
      Date
      N/A - N/A
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 10+ years years
      Requirements Information
      Inclusion and Exclusion Criteria
      Inclusion Criteria
      • At least 10 years of age.
      • Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes
      Exclusion Criteria
      • Has any condition that might interfere with the patient's participation

      Protocol Summary

      Examine red and white blood cells of PNH patients with bone marrow failure syndromes.

      Trial Locations

      No locations found.